Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research focused on Oncology and Erlotinib, with related work in Crizotinib, Lung cancer, Apatinib. Notable publications include 'CTONG 1509: Phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC', 'Expert consensus of management of adverse drug reactions with anaplastic lymphoma kinase tyrosine kinase inhibitors', and 'Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies'.
In toto imaging shows intravascular proliferation promotes transmigration of daughter cells during brain invasion of Cryptococcus neoformans
Current status of PD-(L)1 inhibitor usage in advanced or metastatic non-small cell lung cancer: A national survey of oncologists in China.
Expert consensus of management of adverse drug reactions with anaplastic lymphoma kinase tyrosine kinase inhibitors
Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies
Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant ( <i>EGFR</i> m <sup>+</sup> ) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis.
P83.03 Efficacy of Camrelizumab (SHR-1210) Plus Apatinib in Advanced NSCLC with EGFR Mutation
CTONG 1509: Phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC